Endocrine Today | About 25% of U.S. adults have nonalcoholic fatty liver disease, which is the most common chronic liver condition in the U.S., according to the American Liver Foundation. Nonalcoholic fatty liver disease, known as NAFLD, can progress to nonalcoholic steatohepatitis (NASH), which is a leading indication for liver transplant. However, most patients with NAFLD die of cardiovascular disease, not liver
Share:
GB HealthWatch collaborated with preventive cardiologists to explore and validate the clinical utility of its GBinsight comprehensive genetic testing and analysis. The impacts of genetics on clinical practice were presented by leading physicians at the 2020 National Lipid Association s Scientific Sessions.
SAN DIEGO (PRWEB) December 17, 2020 Genetics was a major theme of the National Lipid Association s (NLA) Scientific Sessions, December 2020. Genetic testing for lipid disorders, polygenic risk scores for atherosclerotic cardiovascular disease (ASCVD) and the implications of genetics on clinical care, medical ethics and identifying individuals at high risk and preventive strategies were among the headlining topics. The clinical utility of GBinsight comprehensive genetic testing and analysis was highlighted by several leading physicians and scientists throughout the sessions.